Cidara Therapeutics Inc - Asset Resilience Ratio
Cidara Therapeutics Inc (CDTX) has an Asset Resilience Ratio of 24.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2018)
This chart shows how Cidara Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Cidara Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cidara Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CDTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $126.37 Million | 24.37% |
| Total Liquid Assets | $126.37 Million | 24.37% |
Asset Resilience Insights
- Good Liquidity Position: Cidara Therapeutics Inc maintains a healthy 24.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cidara Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Cidara Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Cidara Therapeutics Inc (2015–2018)
The table below shows the annual Asset Resilience Ratio data for Cidara Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $79.11 Million | -- |
| 2017-12-31 | 18.35% | $14.50 Million | $79.03 Million | +0.35pp |
| 2016-12-31 | 18.00% | $19.25 Million | $106.96 Million | -22.88pp |
| 2015-12-31 | 40.88% | $44.95 Million | $109.97 Million | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more